###begin article-title 0
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 263 267 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 511 515 511 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
Exudative age-related macular degeneration (exudative AMD) is a common vision-threatening disease, with both environmental and genetic factors contributing to its development. Recently, homozygosity for the 72Met variant of the pigment epithelium-derived factor (PEDF) Met72Thr gene polymorphism () was identified as a novel risk factor for exudative AMD in Chinese patients from Taiwan. The role of this polymorphism, however, has not yet been determined in a white European population. In addition, two other PEDF gene polymorphisms, -5736T>C () and -5304C>T (), have been associated with increased risk of diabetic retinopathy, but have not yet been studied among patients with exudative AMD. The purpose of the present study was thus to investigate a hypothesized association between these PEDF polymorphisms and the presence of exudative AMD in a white European population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
The present case-control study comprised 269 patients with exudative AMD and 155 control subjects. Genotypes of the PEDF polymorphisms were determined by 5'-exonuclease assays (TaqMan).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
PEDF genotype and allele frequencies were not significantly different between AMD patients and control subjects. The two promoter polymorphisms, -5736T>C () and -5304C>T (), were in complete association. Presence of the homozygous PEDF 72 Met/Met genotype was associated with a nonsignificant odds ratio of 1.00 (95% confidence interval: 0.67-1.49, p=0.99). Similarly, presence of the homozygous PEDF -5736 TT genotype or -5304 CC genotype was associated with a nonsignificant odds ratio of 0.99 (95% confidence interval: 0.56 - 1.75, p=0.97). Both promoter polymorphisms were in linkage disequilibrium with the Met72Thr () polymorphism (D'=0.83) and formed three common and one rare haplotype. Haplotype frequencies were similar between AMD patients and control subjects (p>0.05).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Our data suggest that none of the investigated PEDF polymorphisms is likely a major risk factor for exudative AMD in a white European population.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Exudative age-related macular degeneration (exudative AMD) is a major cause of severe visual impairment in patients older than 50 years [1-3]. An impaired balance between pro- and antiangiogenic factors has previously been implicated in the development of choroidal neovascularization in AMD [4-6].
###end p 11
###begin p 12
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 1113 1115 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
Pigment epithelium-derived factor (PEDF), a 50 kDa glycoprotein belonging to the serine proteinase inhibitor family [7-10], is a potent antiangiogenic factor [11,12] and exerts neurotrophic and neuroprotective effects [8,13]. It is synthesized by several different cell types including retinal pigment epithelium (RPE) cells and photoreceptors [14]. Several lines of evidence indicate a role of PEDF in the pathogenesis of exudative AMD. First, immunohistochemical studies have revealed significantly reduced immunoreactivity for PEDF in both RPE cells and in Bruch's membrane of AMD eyes compared with healthy control eyes [6,15]. Second, vitreous PEDF concentrations were found to be significantly decreased in eyes with exudative AMD [16]. Additional evidence comes from an animal laser injury model showing an inverse correlation between PEDF expression and formation of choroidal neovascularizations [17,18]. Finally, the administration of recombinant natural PEDF or adenoviral vector-delivered PEDF has been found either to inhibit the development of choroidal neovascularizations or to reduce its extent [19-21].
###end p 12
###begin p 13
###xml 27 29 27 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 658 662 658 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 932 936 932 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
In 2005, Yamagishi et al. [22] proposed the hypothesis that a PEDF gene polymorphism, which is characterized by a methionine to threonine substitution at amino acid position 72 of PEDF (PEDF Met72Thr [PEDF 311T>C], ) [23], might be a genetic marker for AMD. Indeed, Lin et al. [24] only recently identified this polymorphism as a novel risk factor for exudative AMD in a Taiwan Chinese population. So far, this finding has not yet been replicated in a white European population. This, however, is essential to draw firm conclusions on the potential contribution of gene polymorphisms to exudative AMD risk in populations of different ethic origin. Two other PEDF polymorphisms, -5736T>C () and -5304C>T (), have only recently been associated with diabetic retinopathy, but have not yet been studied in AMD patients [25]. The purpose of the present study was thus to investigate a hypothesized association between the aforementioned PEDF polymorphisms and exudative AMD in a white European population.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 68 80 <span type="species:ncbi:9606">participants</span>
###xml 187 199 <span type="species:ncbi:9606">participants</span>
The study comprised 269 patients with exudative AMD and 155 control participants who were of European origin and living in the same geographical area in the southern part of Austria. All participants were seen at the local Department of Ophthalmology, Medical University of Graz, and gave written informed consent before enrollment. The study was conducted according to the Austrian Gene Technology Act and the guidelines of the local Ethics Committee.
###end p 15
###begin p 16
Exudative AMD was diagnosed by ophthalmoscopic fundus examination, followed by fluorescein/indocyanine angiography revealing choroidal neovascularizations. Exclusion criteria comprised the presence of choroidal polypoidal vasculopathy or secondary choroidal neovascularizations due to pathologic myopia (>6 diopters, spherical equivalent), inflammatory or infectious chrorioretinal diseases, trauma, angioid streaks or hereditary diseases.
###end p 16
###begin p 17
###xml 13 24 <span type="species:ncbi:9606">participant</span>
Each control participant underwent a detailed eye examination that included fundus examination. Exclusion criteria were defined as any evidence of age-related maculopathy (drusen as well as pigmentary changes), macular hemorrhages of any cause, or media opacities leading to impaired visualization of the macula.
###end p 17
###begin title 18
Genotype determination
###end title 18
###begin p 19
###xml 250 254 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 352 359 346 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Venous blood drawn from the antecubital vein was collected in ethylene diamine tetraacetic acid tubes. Genomic DNA was isolated from whole blood using a commercial kit (QIA_AMP DNA blood mini kit; Qiagen, Vienna, Austria) and stored at -20 degreesC. PEDF genotype were determined by 5'-exonuclease assays (TaqMan). Primers and probes are summarized in Table 1. Fluorescence was measured in a lambda Fluoro 320 Plus plate reader (MWG Biotech AG, Penzberg, Germany) using excitation/emission filters of 485/530 nm for probes labeled with fluorescent dye FAM and 530/572 nm for probes labeled with fluorescent dye VIC. The data were exported into Excel format, depicted and analyzed as a scatter plot. The technicians responsible for genotyping were blinded for case/control status.
###end p 19
###begin title 20
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Sequences of primers and probes used for the determination of the PEDF genotypes.
###end title 20
###begin p 21
PEDF genotypes were determined by 5'-exonuclease assays (TaqMan) using probes labeled with fluorescent dyes VIC or FAM. Abbreviations used in the table: F represents forward primer, R represents reverse primer, WT represents wild-type.
###end p 21
###begin title 22
Statistics
###end title 22
###begin p 23
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
SPSS for Windows (release 14.0; SPSS, Inc.) was used for statistical analyses. Continuous variables were analyzed by t-test and presented as mean+/-standard deviation (SD). Categorical variables are presented as percentages and were compared as chi-square test. Odds ratios (OR) and 95% confidence intervals (CI) were determined by logistic regression analysis. The criterion for statistical significance was p<0.05.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 83 90 83 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 92 99 92 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 389 396 389 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 53 65 <span type="species:ncbi:9606">participants</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of AMD patients and control participants are presented in Table 2. Table 3 shows PEDF genotype distribution in AMD patients and controls. In both groups, the observed genotype distributions were in line with those predicted by the Hardy-Weinberg equilibrium. PEDF genotype and allele frequencies were not significantly different between AMD patients and controls (Table 3). The two promoter polymorphisms, -5736T>C () and -5304C>T (), were in complete association.
###end p 25
###begin title 26
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of exudative AMD patients and controls.
###end title 26
###begin p 27
###xml 192 200 <span type="species:ncbi:9606">patients</span>
Numbers are given as n (%). Abbreviations: age-related macular degeneration (AMD); standard deviation (SD). The asterisk indicates that the data on body mass index were available from 205 AMD patients and 151 control subjects.
###end p 27
###begin title 28
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
PEDF genotypes in exudative AMD patients and controls.
###end title 28
###begin p 29
Data indicate the number of eyes with and without exudative age-related macular degeneration (AMD), respectively. Numbers are given as n (%). Neither PEDF genotypes nor minor allele frequencies (MAF) were significantly associated with exudative AMD.
###end p 29
###begin p 30
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Presence of the homozygous PEDF 72 Met/Met genotype was associated with a nonsignificant OR of 1.00 (95% CI: 0.67-1.49, p=0.99). Similarly, presence of the homozygous PEDF-5736 TT genotype or -5304 CC genotype was associated with a nonsignificant OR of 0.99 (95% CI: 0.56-1.75, p=0.97). The observed OR was not substantially altered after adjustment of smoking habits (data not shown).
###end p 30
###begin p 31
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 304 311 304 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
Both promoter polymorphisms were in linkage disequilibrium with the Met72Thr () polymorphism (D'=0.83). In total, three common haplotypes and one rare haplotype were formed by the PEDF polymorphisms investigated in the present study. Haplotype frequencies were similar between AMD patients and controls (Table 4).
###end p 31
###begin title 32
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
PEDF haplotype frequencies in exudative AMD patients and controls.
###end title 32
###begin p 33
###xml 230 238 <span type="species:ncbi:9606">patients</span>
Frequencies of haplotypes formed by PEDF polymorphisms -5736T>C (), -5304C>T () and Met72Thr (). Frequencies of haplotypes formed by PEDF polymorphisms -5736T>C (), -5304C>T () and Met72Thr () did not significantly differ between patients and controls. Frequencies and p values were calculated using the  4.0 software.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
Exudative AMD has previously been shown to have a strong genetic component [26-39]. Only recently, a significantly increased prevalence of the PEDF 72 Met/Met genotype was reported in a Taiwan Chinese population, yielding an OR of 3.9 for exudative AMD [24]. This, however, has not yet been confirmed in other populations of different ethnic origin.
###end p 35
###begin p 36
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 476 480 476 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
To the best of our knowledge, the present study is the first to investigate the potential role of this polymorphism in a white European population. In contrast to the findings of Lin et al. [24], homozygosity for the PEDF 72Met allele was not found to be significantly more prevalent in AMD patients compared with controls. Importantly, our study had a statistical power of 0.8 to detect or exclude an OR greater than or equal to 1.8. Thus, our data strongly suggest that the PEDF Met72Thr polymorphism itself is unlikely a major risk factor for exudative AMD in a white European population.
###end p 36
###begin p 37
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
Interestingly, the PEDF 72Met allele frequency was 0.652 in our control group of white European subjects, which is substantially higher than the PEDF 72Met allele frequency of 0.311 found in a Taiwan Chinese population [24]. This finding indicates that genotype distributions of this polymorphism vary widely between different populations and thus underlines the importance of performing genetic association studies in various ethnicities.
###end p 37
###begin p 38
###xml 3 7 3 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
As PEDF expression in RPE cells is also influenced by other factors such as oxidative stress [40], our finding that the PEDF Met72Thr polymorphism is not associated with exudative AMD risk in an European population does not argue against a role of PEDF in AMD. Beside the Met72Thr polymorphisms, other PEDF gene variations may be associated with exudative AMD. Recently, two polymorphisms in the PEDF promoter, -5736T>C (rs12150053) and -5304C>T (), but not the Met72Thr polymorphism, were found to be associated with diabetic retinopathy [25,41]. The present study is also the first to investigate the potential association of these polymorphisms with exudative AMD. A major finding of our study was that the two polymorphisms did not confer a significantly increased risk for exudative AMD in a white European population.
###end p 38
###begin p 39
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
Currently, the functionality of the PEDF polymorphisms investigated in the present study is unclear. A variety of putative binding sites for transcription factors and two Alu repetitive sequences have been described in the PEDF promoter [9], but the two promoter polymorphisms (-5736T>C [] and -5304C>T []) we investigated do not affect any of these putative binding sites. The Met72Thr polymorphism lies at the end of a helix domain of the PEDF protein and results in the exchange of a hydrophobic amino acid (methionine) by a polar amino acid (threonine) [23]. Nevertheless, the functional consequences of this exchange are currently unknown. Further studies investigating the influence of these polymorphisms on the expression and function of the PEDF protein will be necessary to clarify their functionality.
###end p 39
###begin p 40
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Previous studies have clearly demonstrated that PEDF itself is able to inhibit the development of choroidal neovascularizations [19-21]. Considering the antiangiogenic and anti-vasopermeability effects of PEDF [11,12], it remains to be determined whether gene polymorphisms affecting the expression of PEDF in the chorioretinal tissue may modulate the efficacy as well as frequency of anti-vascular endothelial growth factor treatment. Thus, further studies focusing on the identification of functional PEDF polymorphisms and their potential association with treatment outcome might be of great interest.
###end p 40
###begin title 41
Acknowledgments
###end title 41
###begin p 42
We thank Gabriele Trummer, Christa Wachswender, Manuela Fischl, and Sieglinde Kirchengast for their excellent technical assistance.
###end p 42
###begin title 43
References
###end title 43
###begin article-title 44
Prevalence of age-related maculopathy. The Beaver Dam Eye Study.
###end article-title 44
###begin article-title 45
Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study.
###end article-title 45
###begin article-title 46
Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.
###end article-title 46
###begin article-title 47
Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
###end article-title 47
###begin article-title 48
Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration.
###end article-title 48
###begin article-title 49
###xml 82 87 <span type="species:ncbi:9606">human</span>
Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells.
###end article-title 49
###begin article-title 50
Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family.
###end article-title 50
###begin article-title 51
###xml 83 88 <span type="species:ncbi:9606">human</span>
Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin.
###end article-title 51
###begin article-title 52
###xml 21 26 <span type="species:ncbi:9606">human</span>
Crystal structure of human PEDF, a potent anti-angiogenic and neurite growth-promoting factor.
###end article-title 52
###begin article-title 53
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
###end article-title 53
###begin article-title 54
Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site.
###end article-title 54
###begin article-title 55
PEDF: a multifaceted neurotrophic factor.
###end article-title 55
###begin article-title 56
###xml 81 86 <span type="species:ncbi:9606">human</span>
Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues.
###end article-title 56
###begin article-title 57
###xml 95 100 <span type="species:ncbi:9606">human</span>
Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration.
###end article-title 57
###begin article-title 58
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.
###end article-title 58
###begin article-title 59
Expression of pigment epithelium-derived factor in experimental choroidal neovascularization.
###end article-title 59
###begin article-title 60
###xml 64 67 <span type="species:ncbi:10116">rat</span>
Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization.
###end article-title 60
###begin article-title 61
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization.
###end article-title 61
###begin article-title 62
###xml 105 110 <span type="species:ncbi:9606">human</span>
Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye.
###end article-title 62
###begin article-title 63
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.
###end article-title 63
###begin article-title 64
Met72Thr polymorphism of pigment epithelium-derived factor gene and susceptibility to age-related macular degeneration.
###end article-title 64
###begin article-title 65
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Four polymorphic variations in the PEDF gene identified during the mutation screening of patients with Leber congenital amaurosis.
###end article-title 65
###begin article-title 66
Pigment Epithelium-Derived Factor Gene Met72Thr Polymorphism Is Associated With Increased Risk of Wet Age-related Macular Degeneration.
###end article-title 66
###begin article-title 67
Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy.
###end article-title 67
###begin article-title 68
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.
###end article-title 68
###begin article-title 69
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 69
###begin article-title 70
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 70
###begin article-title 71
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 71
###begin article-title 72
Complement factor H polymorphisms in Japanese population with age-related macular degeneration.
###end article-title 72
###begin article-title 73
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.
###end article-title 73
###begin article-title 74
HTRA1 promoter polymorphism in wet age-related macular degeneration.
###end article-title 74
###begin article-title 75
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.
###end article-title 75
###begin article-title 76
AMD Genetics Clinical Study Group, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
###end article-title 76
###begin article-title 77
Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration.
###end article-title 77
###begin article-title 78
Complement C3 variant and the risk of age-related macular degeneration.
###end article-title 78
###begin article-title 79
Variation in complement factor 3 is associated with risk of age-related macular degeneration.
###end article-title 79
###begin article-title 80
Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.
###end article-title 80
###begin article-title 81
Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
###end article-title 81
###begin article-title 82
Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.
###end article-title 82
###begin article-title 83
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Pigment epithelium-derived factor Met72Thr polymorphism in patients with diabetic microangiopathy.
###end article-title 83

